title: [Myocardial metastasis from renal cell carcinoma treated with sorafenib].
abstract: We present a case of myocardial metastasis from renal cell carcinoma (RCC) during the treatment with sorafenib. A 63-year-old male, who had undergone right radical nephrectomy, received interferon-alpha (IFN), interleukin (IL-2) and 5-flurouracil (5-FU) for the treatment of lung and pleural metastases. However, since this metastasis showed progressive disease, we administered sorafenib. Nine months after the introduction of sorafenib, he complained of dyspnea. Chest computed tomography and cardiac ultrasonography revealed a low density mass at the cardiac muscle of the left cardiac ventricle, suggesting myocardial metastasis of RCC. Molecular targeted therapy achieved a longer survival in advanced RCC patients in comparison with the immunotherapy using cytokines. Therefore, in metastasis evaluation, some organs which have been regarded as rare sites should be carefully evaluated.
authors.affiliation: The Department of Urology, Kitasato University School of Medicine, Japan.
authors.forename: Yoshiko
authors.initials: Y
authors.lastname: Tokuyama
authors.forename: Masatsugu
authors.initials: M
authors.lastname: Iwamura
authors.forename: Tetsuo
authors.initials: T
authors.lastname: Fujita
authors.forename: Atsushi
authors.initials: A
authors.lastname: Sugita
authors.forename: Ryota
authors.initials: R
authors.lastname: Maeyama
authors.forename: Hideharu
authors.initials: H
authors.lastname: Bessho
authors.forename: Wataru
authors.initials: W
authors.lastname: Ishikawa
authors.forename: Ken-ichi
authors.initials: K
authors.lastname: Tabata
authors.forename: Kazunari
authors.initials: K
authors.lastname: Yoshida
authors.forename: Shiro
authors.initials: S
authors.lastname: Baba
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001557:Benzenesulfonates / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000473:pathology*; D006338:Heart Neoplasms / Q000556:secondary*; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D011725:Pyridines / Q000627:therapeutic use*; D000077157:Sorafenib
chemical_list: D000970:Antineoplastic Agents; D001557:Benzenesulfonates; D010671:Phenylurea Compounds; D011725:Pyridines; D009536:Niacinamide; D000077157:Sorafenib